REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Reata Pharmaceuticals, Inc. (NasdaqGM: RETA) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Reata will receive $172.50 in cash for each share of Reata that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-reta/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230828508831/en/

The Reata Pharmaceuticals Registered (A) Stock at the time of publication of the news with a raise of +0,11 % to 169,2USD on Nasdaq stock exchange (28. August 2023, 20:34 Uhr).